We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
Read MoreHide Full Article
Key Takeaways
Viatris is expected to report Q3 revenues of $3.78 billion and earnings of 64 cents per share.
New product growth and strength in branded markets may offset supply disruptions and competitive pressures.
VTRS' China growth benefits from cardiovascular demand, but procurement changes may weigh on hospital sales.
Viatris (VTRS - Free Report) , a global healthcare company, is expected to beat expectations when it reports third-quarter 2026 results on Nov. 5, before the opening bell.
The Zacks Consensus Estimate for third-quarter revenues is pegged at $3.78 billion, while the same for earnings is pinned at 64 cents per share.
VTRS Q3 Earnings: Factors to Consider
The company reports under four segments based on geography — Developed Markets, Emerging Markets, Japan, Australia and New Zealand (“JANZ”) and Greater China.
Developed Markets sales are expected to rise, driven by new product sales. Growth in Creon and Yupelri, along with incremental contributions from newer products like iron sucrose, octreotide, Breyna, and estradiol patches, is likely to have supported Viatris’ top line in the to-be-reported quarter. However, continued sales pressure on Dymista and EpiPen is likely to have partially offset these gains.
Following a June 2024 FDA inspection of Viatris’ oral finished-dose manufacturing facility in Indore, India, the company received a warning letter and an import alert in December 2024. The import alert continues to affect 11 actively distributed products, including lenalidomide and everolimus, restricting their U.S. imports until the warning letter is lifted. Viatris has made progress on remediation and expects the facility to be ready for FDA reinspection soon. The Zacks Consensus Estimate for Developed Markets revenues is pinned at $2.23 billion.
Emerging Markets sales are likely to have been supported by continued strength in the branded business. However, generic sales are likely to have remained under pressure from supply constraints in the antiretroviral business and additional disruptions affecting lower-margin oral solid-dose products from the Nashik facility. The Zacks Consensus Estimate for revenues from this geography is pegged at $565.4 million.
Viatris shares have surged 50% year to date compared with the industry’s 9.6% growth.
Image Source: Zacks Investment Research
Sales in JANZ are likely to have remained under pressure from government price reductions in Japan and additional competition for existing branded products in Australia. These headwinds might have been partially offset by broad volume growth in Japanese generics and strong complex generics performance in Australia. The Zacks Consensus Estimate for revenues from the JANZ markets is pinned at $291.6 million.
Sales in Greater China are likely to have continued growing, driven by sustained demand across e-commerce, retail and hospital channels, supported by increased demand for Viatris' cardiovascular portfolio. However, growth is likely to have moderated due to procurement policy changes that are expected to have negatively impacted hospital-channel volumes. The Zacks Consensus Estimate for revenues from this geography is pegged at $675.4 million.
Viatris also reports revenues under two divisions (in terms of product category) — brands and generics.
The brand business, which accounts for the majority of Viatris' portfolio, is likely to have benefited from continued strength in Greater China and Emerging Markets. However, growth in Greater China might have moderated due to procurement policy changes affecting hospital-channel volumes, while competitive pressure on established brands in Developed Markets might have limited growth.
The generics business is likely to have faced additional supply disruptions, primarily affecting lower-margin oral solid-dose products in Emerging Markets and certain generic products in Europe. New product launches and growth in select Developed Markets products might have partly offset these headwinds. However, additional competition for Breyna and Wixela in North America is likely to have weighed on sales.
On the profitability front, adjusted gross margin is likely to have moderated slightly, as anticipated by management for the second half. Adjusted total operating expenses are likely to have increased marginally, with higher SG&A spending to support upcoming product launches, partly offset by continued cost-saving initiatives.
VTRS’ Impeccable Earnings Surprise History
Viatris’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 10.18%. In the last reported quarter, VTRS beat earnings by 11.29%.
Our proven model predicts an earnings beat for VTRS this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here, as you will see below.
Earnings ESP: Viatris has an Earnings ESP of +0.31%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Here are some other stocks worth considering from the healthcare space, as our model shows that these, too, have the right combination of elements to beat on earnings this reporting cycle.
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and flaunts a Zacks Rank #1 at present.
TGTX shares have surged 101.1% year to date. The company’s earnings missed estimates in three of the trailing four quarters and topped in the remaining one, delivering the average surprise of 184.65%. TG Therapeuticsis scheduled to report third-quarter results on Nov. 9.
Iovance Biotherapeutics (IOVA - Free Report) has an Earnings ESP of +44.44% and a Zacks Rank #2 at present.
IOVA shares have skyrocketed 193.8% year to date. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.82%. Iovance Biotherapeutics is scheduled to report third-quarter results on Nov. 5.
Acadia Pharmaceuticals (ACAD - Free Report) has an Earnings ESP of +8.09% and a Zacks Rank #3 at present.
ACAD shares have lost 23.4% year to date. The company’s earnings beat estimates in three of the trailing four quarters and missed on the remaining occasion, delivering the average surprise of 67.26%. Acadia Pharmaceuticalsis scheduled to report third-quarter results on Nov. 4.
View the Zacks #1 Rank List
Image: Bigstock
Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
Key Takeaways
Viatris (VTRS - Free Report) , a global healthcare company, is expected to beat expectations when it reports third-quarter 2026 results on Nov. 5, before the opening bell.
The Zacks Consensus Estimate for third-quarter revenues is pegged at $3.78 billion, while the same for earnings is pinned at 64 cents per share.
VTRS Q3 Earnings: Factors to Consider
The company reports under four segments based on geography — Developed Markets, Emerging Markets, Japan, Australia and New Zealand (“JANZ”) and Greater China.
Developed Markets sales are expected to rise, driven by new product sales. Growth in Creon and Yupelri, along with incremental contributions from newer products like iron sucrose, octreotide, Breyna, and estradiol patches, is likely to have supported Viatris’ top line in the to-be-reported quarter. However, continued sales pressure on Dymista and EpiPen is likely to have partially offset these gains.
Following a June 2024 FDA inspection of Viatris’ oral finished-dose manufacturing facility in Indore, India, the company received a warning letter and an import alert in December 2024. The import alert continues to affect 11 actively distributed products, including lenalidomide and everolimus, restricting their U.S. imports until the warning letter is lifted. Viatris has made progress on remediation and expects the facility to be ready for FDA reinspection soon. The Zacks Consensus Estimate for Developed Markets revenues is pinned at $2.23 billion.
Emerging Markets sales are likely to have been supported by continued strength in the branded business. However, generic sales are likely to have remained under pressure from supply constraints in the antiretroviral business and additional disruptions affecting lower-margin oral solid-dose products from the Nashik facility. The Zacks Consensus Estimate for revenues from this geography is pegged at $565.4 million.
Viatris shares have surged 50% year to date compared with the industry’s 9.6% growth.
Image Source: Zacks Investment Research
Sales in JANZ are likely to have remained under pressure from government price reductions in Japan and additional competition for existing branded products in Australia. These headwinds might have been partially offset by broad volume growth in Japanese generics and strong complex generics performance in Australia. The Zacks Consensus Estimate for revenues from the JANZ markets is pinned at $291.6 million.
Sales in Greater China are likely to have continued growing, driven by sustained demand across e-commerce, retail and hospital channels, supported by increased demand for Viatris' cardiovascular portfolio. However, growth is likely to have moderated due to procurement policy changes that are expected to have negatively impacted hospital-channel volumes. The Zacks Consensus Estimate for revenues from this geography is pegged at $675.4 million.
Viatris also reports revenues under two divisions (in terms of product category) — brands and generics.
The brand business, which accounts for the majority of Viatris' portfolio, is likely to have benefited from continued strength in Greater China and Emerging Markets. However, growth in Greater China might have moderated due to procurement policy changes affecting hospital-channel volumes, while competitive pressure on established brands in Developed Markets might have limited growth.
The generics business is likely to have faced additional supply disruptions, primarily affecting lower-margin oral solid-dose products in Emerging Markets and certain generic products in Europe. New product launches and growth in select Developed Markets products might have partly offset these headwinds. However, additional competition for Breyna and Wixela in North America is likely to have weighed on sales.
On the profitability front, adjusted gross margin is likely to have moderated slightly, as anticipated by management for the second half. Adjusted total operating expenses are likely to have increased marginally, with higher SG&A spending to support upcoming product launches, partly offset by continued cost-saving initiatives.
VTRS’ Impeccable Earnings Surprise History
Viatris’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 10.18%. In the last reported quarter, VTRS beat earnings by 11.29%.
Viatris Inc. Price, Consensus and EPS Surprise
Viatris Inc. price-consensus-eps-surprise-chart | Viatris Inc. Quote
What Our Model Predicts for Viatris
Our proven model predicts an earnings beat for VTRS this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here, as you will see below.
Earnings ESP: Viatris has an Earnings ESP of +0.31%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: VTRS currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks to Consider
Here are some other stocks worth considering from the healthcare space, as our model shows that these, too, have the right combination of elements to beat on earnings this reporting cycle.
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and flaunts a Zacks Rank #1 at present.
TGTX shares have surged 101.1% year to date. The company’s earnings missed estimates in three of the trailing four quarters and topped in the remaining one, delivering the average surprise of 184.65%. TG Therapeuticsis scheduled to report third-quarter results on Nov. 9.
Iovance Biotherapeutics (IOVA - Free Report) has an Earnings ESP of +44.44% and a Zacks Rank #2 at present.
IOVA shares have skyrocketed 193.8% year to date. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.82%. Iovance Biotherapeutics is scheduled to report third-quarter results on Nov. 5.
Acadia Pharmaceuticals (ACAD - Free Report) has an Earnings ESP of +8.09% and a Zacks Rank #3 at present.
ACAD shares have lost 23.4% year to date. The company’s earnings beat estimates in three of the trailing four quarters and missed on the remaining occasion, delivering the average surprise of 67.26%. Acadia Pharmaceuticalsis scheduled to report third-quarter results on Nov. 4.